Emucare Pharmaceuticals Limited, a prominent Indian pharmaceutical company, has announced its initial public offering (IPO) price range of Rs 960 to Rs 1008 per share. The subscription window opens on July 3, and the company aims to raise Rs 1952 crore through this IPO. Established in 1981, Emucare Pharma has a strong presence in India, Europe, and Canada, and is recognized for its diverse pharmaceutical portfolio.

The IPO consists of a fresh issue of Rs 800 crore and an offer for sale (OFS) of Rs 1151 crore by the company's promoters and shareholders. The proceeds from the fresh issue will be utilized to repay debt and fund general corporate purposes. Emucare Pharma has a significant presence in the Indian market, with a revenue share of 48.28% in FY24. The company's financial performance has been robust, with an operating revenue of Rs 6,658.3 crore and EBITDA of Rs 1,229.7 crore in FY24.

The IPO price range has been set after considering the company's financial performance and market conditions. The upper end of the price band values the company at Rs 18,260 crore. Emucare Pharma's IPO is an opportunity for investors to participate in the company's growth story, which has been marked by its strong presence in the pharmaceutical industry.

Investors should note that the IPO opens on July 3, and the subscription window closes on July 5. The allotment of shares will be done on July 8, and the refund process will initiate on July 9. The company's shares are expected to list on the stock exchanges on July 10. Investors can apply for the IPO through various channels, including UPI, and should ensure that their applications are complete and accurate to avoid any issues.

In conclusion, Emucare Pharma's IPO offers an attractive investment opportunity for those looking to participate in the pharmaceutical industry's growth. With a strong track record and a significant presence in the Indian market, Emucare Pharma is well-positioned for future growth. Investors should carefully consider the IPO details and financial performance before making an informed investment decision.